Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Contact: Mariana Scandizzo (principal investigator)
Not yet recruiting
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432· Phase 3· Eli Lilly and Company· Source
Contact: Antonela Mainardi (principal investigator)
Not yet recruiting
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
NCT07890376· Phase 2· Eli Lilly and Company· Source
Contact: Evelyn Blanc (principal investigator)
Recruiting
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
NCT07783802· Phase 2· Eli Lilly and Company· Source
Contact: Emilio Alaguibe (principal investigator)
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Contact: Emilio Alaguibe (principal investigator)
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Evelyn Blanc (principal investigator)
Active, not recruiting
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800· Phase 3· Biogen· Source
Contact: Mria Smuclir Quevedo (principal investigator)
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122· Phase 3· Eli Lilly and Company· Source
Contact: Evelyn Blanc (principal investigator)
Active, not recruiting
Phase 2b Open-Label Repeat Kidney Biopsy Study
NCT06740526· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Active, not recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722· Phase 3· Eli Lilly and Company· Source
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956· Phase 2· Eli Lilly and Company· Source
Contact: Evelyn Blanc (principal investigator)
Active, not recruiting
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· Phase 3· Eli Lilly and Company· Source